Cathie Wood's Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street ThinksBenzinga • 07/20/26
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology PlatformBusiness Wire • 07/20/26
Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health ServiceBusiness Wire • 07/16/26
Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare CancersBusiness Wire • 06/25/26
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart RhythmBusiness Wire • 06/11/26
Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome TestingBusiness Wire • 06/09/26
Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness Wire • 06/05/26
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding MembersBusiness Wire • 06/03/26